101 related articles for article (PubMed ID: 29069277)
21. The prognostic significance of HER2 positivity for advanced gastric cancer patients undergoing first-line modified FOLFOX-6 regimen.
Kim JW; Im SA; Kim M; Cha Y; Lee KH; Keam B; Kim MA; Han SW; Oh DY; Kim TY; Kim WH; Bang YJ
Anticancer Res; 2012 Apr; 32(4):1547-53. PubMed ID: 22493400
[TBL] [Abstract][Full Text] [Related]
22. Adenocarcinomas of the esophagogastric junction are more likely to respond to preoperative chemotherapy than distal gastric cancer.
Reim D; Gertler R; Novotny A; Becker K; zum Büschenfelde CM; Ebert M; Dobritz M; Langer R; Hoefler H; Friess H; Schumacher C
Ann Surg Oncol; 2012 Jul; 19(7):2108-18. PubMed ID: 22130620
[TBL] [Abstract][Full Text] [Related]
23. Perioperative chemotherapy for resectable gastroesophageal cancer: a single-center experience.
Molina R; Lamarca A; Martínez-Amores B; Gutiérrez A; Blázquez A; López A; Granell J; Álvarez-Mon M
Eur J Surg Oncol; 2013 Aug; 39(8):814-22. PubMed ID: 23755989
[TBL] [Abstract][Full Text] [Related]
24. Novel immune-risk score of gastric cancer: A molecular prediction model combining the value of immune-risk status and chemosensitivity.
Duan S; Wang P; Liu F; Huang H; An W; Pan S; Wang X
Cancer Med; 2019 May; 8(5):2675-2685. PubMed ID: 30945466
[TBL] [Abstract][Full Text] [Related]
25. Development and validation of a gene expression-based signature to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma: a retrospective, multicentre, cohort study.
Tang XR; Li YQ; Liang SB; Jiang W; Liu F; Ge WX; Tang LL; Mao YP; He QM; Yang XJ; Zhang Y; Wen X; Zhang J; Wang YQ; Zhang PP; Sun Y; Yun JP; Zeng J; Li L; Liu LZ; Liu N; Ma J
Lancet Oncol; 2018 Mar; 19(3):382-393. PubMed ID: 29428165
[TBL] [Abstract][Full Text] [Related]
26. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer.
Wu X; Gu J; Wu TT; Swisher SG; Liao Z; Correa AM; Liu J; Etzel CJ; Amos CI; Huang M; Chiang SS; Milas L; Hittelman WN; Ajani JA
J Clin Oncol; 2006 Aug; 24(23):3789-98. PubMed ID: 16785472
[TBL] [Abstract][Full Text] [Related]
27. Perioperative chemotherapy vs. neoadjuvant chemoradiation in gastroesophageal junction adenocarcinoma : A population-based evaluation of the Munich Cancer Registry.
Münch S; Habermehl D; Agha A; Belka C; Combs SE; Eckel R; Friess H; Gerbes A; Nüssler NC; Schepp W; Schmid RM; Schmitt W; Schubert-Fritschle G; Weber B; Werner J; Engel J
Strahlenther Onkol; 2018 Feb; 194(2):125-135. PubMed ID: 29071366
[TBL] [Abstract][Full Text] [Related]
28. Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses.
Park SH; Sohn TS; Lee J; Lim DH; Hong ME; Kim KM; Sohn I; Jung SH; Choi MG; Lee JH; Bae JM; Kim S; Kim ST; Park JO; Park YS; Lim HY; Kang WK
J Clin Oncol; 2015 Oct; 33(28):3130-6. PubMed ID: 25559811
[TBL] [Abstract][Full Text] [Related]
29. Correlation of pathological complete response with survival after neoadjuvant chemotherapy in gastric or gastroesophageal junction cancer treated with radical surgery: A meta-analysis.
Li Z; Shan F; Wang Y; Zhang Y; Zhang L; Li S; Jia Y; Xue K; Miao R; Li Z; Ji J
PLoS One; 2018; 13(1):e0189294. PubMed ID: 29370182
[TBL] [Abstract][Full Text] [Related]
30. Perineural invasion after preoperative chemotherapy predicts poor survival in patients with locally advanced gastric cancer: gene expression analysis with pathologic validation.
Jhawer M; Coit D; Brennan M; Qin LX; Gonen M; Klimstra D; Tang L; Kelsen DP; Shah MA
Am J Clin Oncol; 2009 Aug; 32(4):356-62. PubMed ID: 19381079
[TBL] [Abstract][Full Text] [Related]
31. A clinical prognostic scoring system for resectable gastric cancer to predict survival and benefit from paclitaxel- or oxaliplatin-based adjuvant chemotherapy.
Qian J; Qian Y; Wang J; Gu B; Pei D; He S; Zhu F; Røe OD; Xu J; Liu L; Gu Y; Guo R; Yin Y; Shu Y; Chen X
Drug Des Devel Ther; 2016; 10():241-58. PubMed ID: 26966350
[TBL] [Abstract][Full Text] [Related]
32. Neutrophil count and the inflammation-based glasgow prognostic score predict survival in patients with advanced gastric cancer receiving first-line chemotherapy.
Li QQ; Lu ZH; Yang L; Lu M; Zhang XT; Li J; Zhou J; Wang XC; Gong JF; Gao J; Li J; Li Y; Shen L
Asian Pac J Cancer Prev; 2014; 15(2):945-50. PubMed ID: 24568523
[TBL] [Abstract][Full Text] [Related]
33. Tumor-infiltrating Neutrophils is Prognostic and Predictive for Postoperative Adjuvant Chemotherapy Benefit in Patients With Gastric Cancer.
Zhang H; Liu H; Shen Z; Lin C; Wang X; Qin J; Qin X; Xu J; Sun Y
Ann Surg; 2018 Feb; 267(2):311-318. PubMed ID: 27763900
[TBL] [Abstract][Full Text] [Related]
34. The role of oxaliplatin in the adjuvant setting of different Lauren's type of gastric adenocarcinoma after D2 gastrectomy: a real-world study.
Cheng X; Yu S; Wang Y; Cui Y; Li W; Yu Y; Tang C; Jiang H; Ji Y; Sun Y; Wang X; Shen Z; Liu F; Liu TS
Gastric Cancer; 2019 May; 22(3):587-597. PubMed ID: 30426294
[TBL] [Abstract][Full Text] [Related]
35. A reliable risk score for stage IV esophagogastric cancer.
Blank S; Lordick F; Dobritz M; Grenacher L; Burian M; Langer R; Roth W; Schaible A; Becker K; Bläker H; Sisic L; Stange A; Compani P; Schulze-Bergkamen H; Jäger D; Büchler M; Siewert JR; Ott K
Eur J Surg Oncol; 2013 Aug; 39(8):823-30. PubMed ID: 23375470
[TBL] [Abstract][Full Text] [Related]
36. Effects of genetic polymorphisms in the ABCB1 gene on clinical outcomes in patients with gastric cancer treated by second-line chemotherapy.
Shitara K; Matsuo K; Ito S; Sawaki A; Kawai H; Yokota T; Takahari D; Shibata T; Ura T; Ito H; Hosono S; Kawase T; Watanabe M; Tajima K; Yatabe Y; Tanaka H; Muro K
Asian Pac J Cancer Prev; 2010; 11(2):447-52. PubMed ID: 20843132
[TBL] [Abstract][Full Text] [Related]
37. Development and Validation of a Six-Gene Recurrence Risk Score Assay for Gastric Cancer.
Lee KW; Lee SS; Hwang JE; Jang HJ; Lee HS; Oh SC; Lee SH; Sohn BH; Kim SB; Shim JJ; Jeong W; Cha M; Cheong JH; Cho JY; Lim JY; Park ES; Kim SC; Kang YK; Noh SH; Ajani JA; Lee JS
Clin Cancer Res; 2016 Dec; 22(24):6228-6235. PubMed ID: 27654712
[TBL] [Abstract][Full Text] [Related]
38. Perioperative chemotherapy versus postoperative chemoradiotherapy in patients with resectable gastric/gastroesophageal junction adenocarcinomas: A survival analysis of 5058 patients.
Fitzgerald TL; Efird JT; Bellamy N; Russo SM; Jindal C; Mosquera C; Holliday EG; Biswas T
Cancer; 2017 Aug; 123(15):2909-2917. PubMed ID: 28386965
[TBL] [Abstract][Full Text] [Related]
39. Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial.
Touchefeu Y; Guimbaud R; Louvet C; Dahan L; Samalin E; Barbier E; Le Malicot K; Cohen R; Gornet JM; Aparicio T; Nguyen S; Azzedine A; Etienne PL; Phelip JM; Hammel P; Chapelle N; Sefrioui D; Mineur L; Lepage C; Bouche O
Gastric Cancer; 2019 May; 22(3):577-586. PubMed ID: 30311042
[TBL] [Abstract][Full Text] [Related]
40. Intraoperatively assessed macroscopic serosal changes in patients with curatively resected advanced gastric cancer: clinical implications for prognosis and peritoneal recurrence.
Yoo C; Ryu MH; Park YS; Yoo MW; Park SR; Ryoo BY; Jang SJ; Yook JH; Kim BS; Kang YK
Ann Surg Oncol; 2015 Sep; 22(9):2940-7. PubMed ID: 25605515
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
